The world of weight loss is about to get a shake-up, and Amazon is at the forefront! Amazon Pharmacy has just added a groundbreaking weight-loss pill to its digital shelves, marking a significant step in the e-commerce giant's healthcare journey. But is this a game-changer for obesity treatment?
Amazon announced on Friday that it is now offering Wegovy, a weight-loss pill developed by Novo Nordisk, through its online pharmacy service. This move comes as Novo Nordisk introduces an oral version of its injectable obesity drug Wegovy in the U.S. market. The pill is priced at $149 per month for cash-paying patients, but patients with insurance can get it for as low as $25 a month.
Here's the intriguing part: Wegovy enters the market with some of the lowest cash prices in the obesity and diabetes drug arena, a space traditionally dominated by expensive weekly injections from Novo Nordisk and Eli Lilly. By making Wegovy available on its platform, Amazon supports Novo Nordisk's strategy to break free from conventional distribution channels and reach a broader patient base.
Amazon's pricing strategy is straightforward: eligible customers with insurance can pay as little as $25 for a month's supply, while those without insurance can opt for the cash-pay option starting at $149 per month. In the coming weeks, Amazon will also make Wegovy accessible through its prescription vending kiosks located in select One Medical clinics, adding another layer of convenience.
Amazon Pharmacy, launched in 2020, is the company's ambitious foray into the U.S. healthcare industry, valued at multitrillion dollars. This venture began with the acquisition of online pharmacy PillPack in 2018 for approximately $750 million, followed by the purchase of primary-care clinic One Medical in 2022 for a staggering $3.9 billion. Amazon's strategy is clear: attract customers with fast delivery and transparent pricing, offering same-day prescription delivery to nearly half of U.S. consumers.
While Amazon hasn't revealed the number of Amazon Pharmacy users, analysts estimate it could rake in a whopping $2 billion in annual revenue. The service has already partnered with WeightWatchers to deliver weight-loss medications to its members and collaborated with Eli Lilly to distribute prescription drugs, including its obesity medication Zepbound, purchased through Eli Lilly's direct-to-consumer website.
The Wegovy pill is now available at over 70,000 U.S. pharmacies, including CVS and Costco, as well as select telehealth providers like Ro, LifeMD, Weight Watchers, GoodRx, and Novo Nordisk's own NovoCare Pharmacy. Cash-paying patients can also access the starting dose for $149 per month on President Donald Trump's direct-to-consumer website, TrumpRx, following a deal struck with his administration in November 2025. But here's where it gets controversial: the launch date of the TrumpRx website is unclear, leaving some to question the timing and motives.
Health experts believe that oral medications like Wegovy could significantly expand obesity treatment options in the U.S., reaching individuals who were previously hesitant to try injectable treatments due to needle phobia or concerns about the perceived intensity of injections. And this is the part most people miss: the potential impact on public health could be massive.
As if the story wasn't intriguing enough, Eli Lilly is set to release its own rival obesity pill later this year, pending Food and Drug Administration approval. The stage is set for a fascinating battle in the weight-loss market, leaving us with one burning question: will these oral medications revolutionize obesity treatment, or will they face unexpected challenges? Share your thoughts in the comments below!
